Form 4: Pacira BioSciences Chief Medical Officer Reports Stock Transactions

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports the sale of shares to cover tax obligations and pursuant to a pre-arranged trading plan.

Summary

• On August 1, 2024, Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, sold 305 shares of common stock at $20.75 per share to cover tax obligations upon the vesting of restricted stock units.
• On August 2, 2024, Slonin sold 945 shares of common stock at $20.05 per share pursuant to a Rule 10b5-1 trading plan.
• Following these transactions, Slonin beneficially owns 94,306.746 shares of Pacira BioSciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is a standard practice in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, including pharmaceutical firms like Pacira BioSciences.
• The use of Rule 10b5-1 trading plans is a common method for insiders to sell shares while avoiding accusations of trading on non-public information, aligning with industry best practices.

Stakeholder Impact

• The stock sales by a key executive could be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the reasons behind the sales.
• The use of a 10b5-1 plan suggests a planned and orderly approach to selling shares, which can reassure investors.

Key Dates